We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4
Read MoreHide Full Article
Penumbra, Inc. (PEN - Free Report) reported fourth-quarter 2018 earnings per share (EPS) of 13 cents, up 30% year over year. The figure surpassed the Zacks Consensus Estimate of 11 cents by 18.2%. However, the stock movement does not reflect the company’s promising earnings results as it lost 4.2% to close at $140.52 on Mar 1 since the release.
The company reported 2018 adjusted earnings of 51 cents, beating the Zacks Consensus Estimate by 6.3%. The figure also compares favorably with the year-ago loss of a penny.
Revenues in the quarter rose 25.8% year over year (up 26.9% at constant exchange rate or CER) to $120.8 million, exceeding the Zacks Consensus Estimate of $114.6 million.
Net revenues in 2018 totaled $444.9 million, outpacing the Zacks Consensus Estimate of $438.7 million. The figure also improved 33.3% (up 32.2% at CER) from the year-ago level.
On a geographic basis, fourth-quarter revenues in the United States (representing 67% of total sales) grossed $80.6 million, up 30.9% from the year-ago quarter (same at CER). Meanwhile, international sales (33% of total sales) advanced 16.6% year over year (up 19.7% at CER) to $40.1 million.
Going by product category, revenues from neuro products grew 9.9% (up 11.2% at CER) to $74 million in the quarter under review. Revenues from peripheral vascular product business rose to $46.8 million in the fourth quarter, reflecting an increase of 62.8% (up 63.6% at CER) year over year.
Operational Update
Penumbra’s fourth-quarter gross margin was 65.2%, reflecting a 110-basis point (bps) contraction year over year. Gross profit rose 23.5%.
Research and development expenses totaled $10.9 million, up 29.8% year over year, while sales, general and administrative expenses amounted to $61.2 million, up 18.8%. Operating profit in the reported quarter came in at $6.7 million, up 71.8% year over year.
Financial Update
Penumbra exited 2018 with cash and cash equivalents of $67.9 million as compared with $50.6 million at the end of 2017.
Outlook
Penumbra has provided guidance for 2019 revenues. The company expects total revenues in the range of $525-$535 million. The Zacks Consensus Estimate of $529.7 million is within the guided range.
Our Take
Penumbra exited fourth-quarter 2018 with better-than-expected results. The year-over-year comparison of earnings was favorable. Moreover, the company witnessed strong growth across all geographies and product lines. The company is focusing on product innovation through research and development. The management also seems to be excited about the launch of the peripheral embolization products into new international markets.
Penumbra is an active player in the fast-growing interventional therapies space. In fact, the company’s products primarily cater to the unmet clinical needs in two major markets — neuro and peripheral vascular.
Zacks Rank & Other Key Picks
Penumbra has a Zacks Rank #2 (Buy).
Other top-ranked stocks that posted solid quarterly results are Varian Medical Systems , AngioDynamics (ANGO - Free Report) and CONMED Corporation (CNMD - Free Report) .
Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2.
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock has a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4
Penumbra, Inc. (PEN - Free Report) reported fourth-quarter 2018 earnings per share (EPS) of 13 cents, up 30% year over year. The figure surpassed the Zacks Consensus Estimate of 11 cents by 18.2%. However, the stock movement does not reflect the company’s promising earnings results as it lost 4.2% to close at $140.52 on Mar 1 since the release.
The company reported 2018 adjusted earnings of 51 cents, beating the Zacks Consensus Estimate by 6.3%. The figure also compares favorably with the year-ago loss of a penny.
Revenues in the quarter rose 25.8% year over year (up 26.9% at constant exchange rate or CER) to $120.8 million, exceeding the Zacks Consensus Estimate of $114.6 million.
Net revenues in 2018 totaled $444.9 million, outpacing the Zacks Consensus Estimate of $438.7 million. The figure also improved 33.3% (up 32.2% at CER) from the year-ago level.
Penumbra, Inc. Price, Consensus and EPS Surprise
Penumbra, Inc. Price, Consensus and EPS Surprise | Penumbra, Inc. Quote
On a geographic basis, fourth-quarter revenues in the United States (representing 67% of total sales) grossed $80.6 million, up 30.9% from the year-ago quarter (same at CER). Meanwhile, international sales (33% of total sales) advanced 16.6% year over year (up 19.7% at CER) to $40.1 million.
Going by product category, revenues from neuro products grew 9.9% (up 11.2% at CER) to $74 million in the quarter under review. Revenues from peripheral vascular product business rose to $46.8 million in the fourth quarter, reflecting an increase of 62.8% (up 63.6% at CER) year over year.
Operational Update
Penumbra’s fourth-quarter gross margin was 65.2%, reflecting a 110-basis point (bps) contraction year over year. Gross profit rose 23.5%.
Research and development expenses totaled $10.9 million, up 29.8% year over year, while sales, general and administrative expenses amounted to $61.2 million, up 18.8%. Operating profit in the reported quarter came in at $6.7 million, up 71.8% year over year.
Financial Update
Penumbra exited 2018 with cash and cash equivalents of $67.9 million as compared with $50.6 million at the end of 2017.
Outlook
Penumbra has provided guidance for 2019 revenues. The company expects total revenues in the range of $525-$535 million. The Zacks Consensus Estimate of $529.7 million is within the guided range.
Our Take
Penumbra exited fourth-quarter 2018 with better-than-expected results. The year-over-year comparison of earnings was favorable. Moreover, the company witnessed strong growth across all geographies and product lines. The company is focusing on product innovation through research and development. The management also seems to be excited about the launch of the peripheral embolization products into new international markets.
Penumbra is an active player in the fast-growing interventional therapies space. In fact, the company’s products primarily cater to the unmet clinical needs in two major markets — neuro and peripheral vascular.
Zacks Rank & Other Key Picks
Penumbra has a Zacks Rank #2 (Buy).
Other top-ranked stocks that posted solid quarterly results are Varian Medical Systems , AngioDynamics (ANGO - Free Report) and CONMED Corporation (CNMD - Free Report) .
Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2.
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock has a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>